Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Acceptance Letter - TachoSil, June 26, 2009

Our STN: 125351/0

Nycomed Danmark ApS
Attention: Ms. Camilla Wamberg
Langebjerg 1
DK-4000 Roskilde

Dear Ms. Wamberg:

We have reviewed your June 26, 2009, submission to your biologics license application (BLA) for Fibrin Sealant requesting a proprietary name review. 

In consultation with CBER's Advertising and Promotional Labeling Branch (APLB), we have considered your proposed proprietary name TachoSil and conclude that under 21 CFR Part 201 the proposed proprietary name is acceptable at this time. 

We will perform another proprietary name review of TachoSil closer to the time of the action due date to ensure that we have not approved a conflicting proprietary name for another product in the interim.

If you have any questions, please contact the Regulatory Project Manager, Jie He, at (301) 827-9167.

Sincerely yours,


Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Page Last Updated: 05/04/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English